H. Lundbeck A/S held its Annual General Meeting on 30 March 2011 at the company's registered office

At the general meeting the report by the Supervisory Board was adopted and the
Annual Report was approved.

The general meeting approved the remuneration for the Supervisory Board for the
current financial year.

The general meeting approved the dividend of DKK 3.77 per share of DKK 5 nominal
value proposed by the Supervisory Board.

Thorleif Krarup, Peter Kürstein, Mats Pettersson and Jes Østergaard were re-
elected and Christian Dyvig and Håkan Björklund were elected to the Supervisory
Board. Immediately after the general meeting, the Supervisory Board elected Mats
Pettersson Chairman and Thorleif Krarup Vice-Chairman of the Supervisory Board.


After having elected its Chairman and Vice-Chairman, the Supervisory Board
appointed members for the Audit Committee, the Remuneration Committee and the
Scientific Committee.

Peter Kürstein (committee chairman), Thorleif Krarup and Mats Pettersson were
elected as members of the Audit Committee. Mats Pettersson (committee chairman),
Håkan Bjørklund and Jes Østergaard were elected as members of the Remuneration
Committee. Jes Østergaard (committee chairman), Håkan Bjørklund and Christian
Dyvig were elected as members of the Scientific Committee.

The Supervisory Board of H. Lundbeck A/S will hereafter comprise:

  * Mats Pettersson (Chairman)
  * Thorleif Krarup (Vice-Chairman)
  * Peter Kürstein
  * Jes Østergaard
  * Christian Dyvig
  * Håkan Björklund
  * Mona Elisabeth Elster (employee representative)
  * Jørn Møller Mayntzhusen (employee representative)
  * Kim Rosenville Christensen (employee representative)


Deloitte Statsautoriseret Revisionsaktieselskab was re-appointed as the
company's auditor.

The proposal by the Supervisory Board to adapt the Company's "Remuneration
guidelines for the Supervisory Board and the Executive Management of H. Lundbeck
A/S" so as to comply with the Recommendations on Corporate Governance was
approved.

No other business was transacted at the general meeting.

The Supervisory Board



The content of this release will have no influence on the Lundbeck Group's
financial result for 2011.

Lundbeck contacts

Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen

Investor Relations Officer

+45 36 43 38 16



Jacob Tolstrup

Vice President

+1 847 282 5713


About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2010,
the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.


[HUG#1501756]